NCT05578287 2023-12-07
DETECT
Sun Yat-sen University
Phase 2 Unknown
Clinical Trials
10 trialsNCT06078982 2023-10-12
Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer
Shanghai East Hospital
Phase 1 Unknown
NCT06074484 2023-10-10
A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT05979740 2023-08-31
RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC
RenJi Hospital
Phase 2 Unknown
NCT05723991 2023-02-13
Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma
Tongji Hospital
Phase 4 Unknown
NCT05726175 2023-02-13
Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer
West China Hospital
Phase 2 Unknown
NCT05627414 2022-11-25
Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05493683 2022-10-21
Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05333809 2022-04-20
Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT05016973 2021-08-23
A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown